TL1A Binding Proteins With Engineered CDRs for Fewer Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biologics targeting TNF are associated with serious side effects, highlighting the need for improved therapies targeting TL1A in inflammatory diseases such as Crohn's disease and ulcerative colitis.
Innovation Solution
Development of TL1A binding proteins with specific CDR sequences and immunoglobin Fc domains, including amino acid modifications, to target TL1A and modulate its signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current biologics targeting TNF are used to treat inflammatory diseases, then therapeutic effect is achieved, but serious side effects occur
Solution Approach 1:
The patent extracts and targets TL1A specifically rather than using broad TNF inhibitors. By designing antibodies that bind specifically to TL1A (a particular cytokine within the TNF pathway), the therapy achieves anti-inflammatory effects while avoiding the systemic side effects associated with non-specific TNF blockade.
Solution Approach 2:
The patent applies local quality by creating therapies with targeted specificity. The CDR sequences are engineered to recognize specific epitopes on TL1A, ensuring that the therapeutic action is localized to the TL1A pathway rather than affecting all TNF-mediated processes, thereby reducing off-target side effects.
2Manufacturing precision
If TL1A binding proteins with specific CDR sequences are developed, then targeting specificity is improved, but manufacturing complexity increases
Solution Approach 1:
The patent employs parameter changes by modifying specific amino acid sequences in the CDR regions of the antibody variable domains. These precise sequence changes (e.g., specific substitutions at defined positions) alter the binding specificity and affinity for TL1A, achieving high targeting precision through controlled molecular parameter adjustments.
Solution Approach 2:
The patent segments the antibody structure into functional regions with specific responsibilities. The CDR1, CDR2, and CDR3 regions are independently optimized with specific sequence requirements, allowing each segment to contribute to different aspects of TL1A binding recognition and affinity, thereby achieving high specificity through modular design.
Data Source
AI summary
Provided herein are TL1A binding proteins (e.g., antibodies that bind TL1A) and methods of use.